Skip to search formSkip to main contentSkip to account menu

tasosartan

Known as: 5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one, taso-sartan 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Angiotensin-receptor blockers (ARBs) were first introduced into the marketplace in the early 1990s and have been used to treat… 
Review
2001
Review
2001
  • T. Unger
  • Blood pressure. Supplement
  • 2001
  • Corpus ID: 45314205
Angiotensin II mediates its haemodynamic effects by binding to specific cell-surface receptors. In humans, two receptor subtypes… 
Review
2000
Review
2000
  • R. Dina, M. Jafari
  • American journal of health-system pharmacy : AJHP…
  • 2000
  • Corpus ID: 51737
Angiotensin II (AT-II)-receptor antagonists are reviewed. Research focused on blocking the renin-angiotensin system (RAS) led to… 
2000
2000
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its… 
Review
1999
Review
1999
  • P. Timmermans
  • Hypertension research : official journal of the…
  • 1999
  • Corpus ID: 9727638
Acceptance of the notion that physiologically specific interruption of the renin-angiotensin-aldosterone system (RAAS) is of… 
Review
1999
Review
1999
  • P. Timmermans
  • The Canadian journal of cardiology
  • 1999
  • Corpus ID: 24694991
The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists… 
1998
1998
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist… 
1998
1998
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal…